AcinetoVax (VXD001)
Infections caused by multi-drug resistant Acinetobacter baumannii
Pre-clinicalActive
Key Facts
Indication
Infections caused by multi-drug resistant Acinetobacter baumannii
Phase
Pre-clinical
Status
Active
Company
About VAXDYN
VAXDYN is a private, pre-revenue biotech focused on developing novel vaccines against multi-drug resistant bacterial pathogens, a critical threat in the post-antibiotic era. Its core technology platform transforms an inactivated, LPS-null (endotoxin-free) whole-cell vaccine candidate into multivalent vaccines targeting 'superbugs' like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The company is supported by non-dilutive funding (e.g., CARB-X, EU grants) and is advancing its lead candidate, AcinetoVax, towards clinical development while expanding its pipeline.
View full company profile